Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0RZJIL)
| ADC Name |
Tamrintamab pamozirine
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
tamrintamab pamozirine; SC-003; DC-1728001
Click to Show/Hide
|
|||||
| Organization |
Stemcentrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Tamrintamab
|
Antibody Info | ||||
| Antigen Name |
Dipeptidase 3 (DPEP3)
|
Antigen Info | ||||
| Payload Name |
SG3199 (SC-DR002)
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
pamozirine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) |
1.72%
|
|||
| Patients Enrolled |
Female patients (age 18 years) with EOC if they had evidence of progressive disease during or within 6 months of receiving a platinum regimen.
|
||||
| Administration Dosage |
1 of 6 dose levels (0.025-0.40 mg/kg) every 3 weeks (Q3W), utilizing a standard 3+3 design (dose-limiting toxicity [DLT] period: 21 days).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02539719 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1a/1b dose escalation and expansion study of SC-003 as a single-agent and in combination with ABBV-181 in subjects with platinum-resistant/ refractory ovarian cancer. | ||||
| Primary Endpoint |
The MTD for the Q3W schedule was 0.30 mg/kg and the SC-003 doses selected for the dose-expansion phase of the study were 0.30 mg/kg and 0.20 mg/kg.
|
||||
| Other Endpoint |
ORR=5.17% (N=3/58), 3 patients achieved PR. All responses were observed at 0.20-0.30mg/kg. Responses were not durable, with only 1 PR confirmed on the follow-up 16-week scan.
|
||||
References